Biohaven (BHVN) vs Structure Therapeutics (GPCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Structure Therapeutics (GPCR) has outperformed Biohaven (BHVN) over the past year, losing 9.8% versus a loss of 20.9%. Structure Therapeutics is the larger company by market cap ($1.83 billion vs $1.80 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | GPCR |
|---|---|---|
| Share price | $11.93 | $25.67 |
| Market cap | $1.80B | $1.83B |
| 1-day change | +0.42% | -3.79% |
| YTD return | +5.23% | -63.09% |
| 1-year return | -20.91% | -9.77% |
| EPS (TTM) | $-4.56 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.57 | $94.90 |
| 52-week low | $7.48 | $25.09 |
| Distance from 52-week high | -35.74% | -72.95% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +78.29% | +312.08% |
| Average volume | 2.62M | 965.00K |
| Shares outstanding | 151.04M | 71.31M |
| Employees | 274 | 281 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GPCR has outperformed BHVN by 11.1 percentage points over the past year.
- The two companies sit in different sectors: Biohaven in Health Care and Structure Therapeutics in Healthcare.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Healthcare · Biotechnology · 281 employees
BHVN vs GPCR FAQ
Which is bigger, Biohaven or Structure Therapeutics?
Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.83B compared with $1.80B for Biohaven (BHVN).
Which stock has performed better over the past year, BHVN or GPCR?
GPCR returned -9.77% over the past 12 months, compared with -20.91% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Structure Therapeutics in the same industry?
No. Biohaven is in the Health Care sector, while Structure Therapeutics is in Healthcare.